| Previous Close | 1.9100 |
| Open | 1.9000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.8700 - 1.9199 |
| 52 Week Range | 1.4550 - 2.3000 |
| Volume | |
| Avg. Volume | 327,821 |
| Market Cap | 115.18M |
| Beta (5Y Monthly) | 1.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2800 |
| Earnings Date | Nov 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
GlobeNewswireSeer Showcases Scalable Proteomic Advancements Impacting Alzheimer’s, Population Health, and Xenotransplantation at HUPO 2024
Seer’s Proteograph™ Product Suite reveals new insights into Alzheimer’s pathways, drives population-scale plasma analysis, and captures immune dynamics in xenotransplantation—with additional breakthrough research from collaborators advancing proteomic discovery at scaleREDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a leading life science innovator shaping the future of proteomics, is set to present significant advancements at the 23rd Human Proteome Organizat
- GlobeNewswire
Seer to Report Third Quarter 2024 Financial Results on November 6, 2024
REDWOOD CITY, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 6, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s website at investo
